Theravance Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary

Theravance Biopharma

12/08/2025 22:01

Theravance Biopharma Inc TBPH.OQ reported a quarterly adjusted loss of 54 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -28 cents.  The mean expectation of five analysts for the quarter was for earnings of 67 cents per share. Wall Street expected results to range from -28 cents to $4.35 per share.

Revenue rose 83.7% to $26.20 million from a year ago; analysts expected $26.03 million.

Theravance Biopharma Inc's reported EPS for the quarter was $1.08​.

The company reported quarterly net income of $54.84 million.

Theravance Biopharma Inc shares had risen by 3.4% this quarter and gained 21.1% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 373.3% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Theravance Biopharma Inc is $15.00, about 24% above its last closing price of $11.40

This summary was machine generated from LSEG data August 12 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
0.67
-0.54
Missed
Mar. 31 2025
-0.23
-0.27
Missed
Dec. 31 2024
-0.21
-0.31
Missed
Sep. 30 2024
-0.23
-0.26
Missed